Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Fundings And Goals To Match Raised In Latest MDUFA IV Session

This article was originally published in The Gray Sheet

Executive Summary

As the number of de novo applications and pre-submission consultations keep growing, FDA is proposing to institute provide new funding for these programs, among a range of additional proposals laid out in a recent closed-door negotiation. The agency's plan aligns somewhat with an industry proposal, according to meeting minutes, but there is also a lot to negotiate.


Related Content

Senate Seeks Performance Data From FDA On De Novos, Postmarket Surveillance
MDUFA Negotiations Mellow Out Over Opposing Wish Lists
User-Fee Sticker Shock? Industry Pursues Trimmed-Down MDUFA IV Proposal
Shuren In The Lion’s Den: Device Center Chief Defends LDT Plan At Clinical Lab Meeting, Fields Wide Array Of Questions
Industry, FDA Outline Costs Of New MDUFA Proposals; Quality Management A Strong Focus
FDA Counter-Offers On Industry CLIA Waiver Proposal
FDA MDUFA III Performance, By The Numbers
Industry Challenges FDA's User Fee Markup
Hamburg: Neither U.S. Nor EU Device Regulation Has It Completely Right
Successful De Novo Petitions Double With Advent Of Direct Route





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts